Cardiovascular and Soft Tissue Repair Patches Market Report 2025

This Cardiovascular And Soft Tissue Repair Patches market report covers market characteristics, size & growth, segmentation, regional & country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The cardiovascular and soft tissue repair patches market size has grown rapidly in recent years. It will grow from $4.39 billion in 2024 to $4.88 billion in 2025 at a compound annual growth rate (CAGR) of 11.2%. The growth in the historic period can be attributed to aging population, rise in chronic diseases, awareness and early detection, healthcare infrastructure growth, and high demand for hernia repairs.

The cardiovascular and soft tissue repair patches market size is expected to see rapid growth in the next few years. It will grow to $7.38 billion in 2029 at a compound annual growth rate (CAGR) of 10.9%. The growth in the forecast period can be attributed to minimally invasive procedures, enhanced diagnostic tools, increasing demand for personalized medicine, and increasing research and development. Major trends in the forecast period include technological innovations, advancements in surgical techniques, advancements in regenerative medicine, 3D printing, the use of data analytics and artificial intelligence (ai).

The increasing demand for patches related to cardiac disease is projected to drive the growth of the cardiovascular and soft tissue repair patches market. Cardiac disease encompasses a range of disorders associated with the heart and blood vessels. The rising need for patches addressing cardiac conditions is largely influenced by lifestyle factors, including smoking and alcohol consumption. For instance, in May 2024, the Centers for Disease Control and Prevention (CDC), a national public health agency based in Georgia, reported that in 2022, heart disease led to 702,880 deaths, accounting for 1 in every 5 fatalities. This equates to one individual succumbing to cardiovascular disease every 33 seconds. Each year, about 805,000 people in the United States suffer a heart attack, of which 605,000 are experiencing their first heart attack, while 200,000 have had a previous heart attack. Thus, the increasing demand for patches related to cardiac disease is expected to drive the cardiovascular and soft tissue repair patches market in the coming years.

Anticipated growth in the cardiovascular and soft tissue repair patches market is further propelled by government initiatives focused on research and development in healthcare. Government authorities are actively involved in implementing programs, policies, and projects to address healthcare challenges, achieve specific goals, and foster positive societal changes. In 2022, the UK government, through the Department of Health and Social Care, announced a substantial investment of £260 million (US $270.65 million) to boost healthcare research and manufacturing. This commitment aims to support NHS-led health research by introducing privacy-preserving platforms and clinical research services. Additionally, £60 million (US $63.6 million) has been allocated to facilitate the expansion of life sciences manufacturing in the UK. Thus, government initiatives in healthcare research and development play a pivotal role in propelling the cardiovascular and soft tissue repair patches market.

A significant trend gaining traction in the cardiovascular and soft tissue repair patches market is the integration of technological advancements. Companies operating in this sector are actively engaged in developing innovative products and technologies to meet growing market demands. In October 2022, Dozee, an India-based healthcare technology company, introduced an AI-based ECG patch designed for remote cardiac monitoring. This ECG patch, characterized by its small, flexible, and lightweight design, provides a convenient solution for physicians to remotely receive alerts and access live and continuous ECG data from patients. The incorporation of such technological advancements contributes to the overall growth and relevance of the cardiovascular and soft tissue repair patches market.

Leading companies in the cardiovascular and soft tissue repair patches market are actively engaged in developing innovative products, including single-use heart patches, to drive market revenues. The single-use heart patch is an adhesive medical device designed to be directly applied to the heart, providing mechanical support and reducing the stretching of the heart muscle. In October 2022, Mawi, a prominent US-based medical device company, introduced the Mawi Heart Patch - a single-use, two-lead cardiac monitor capable of real-time heart health tracking. This innovative patch offers flexibility in application, allowing for in-clinic or at-home use, and can be worn by patients for up to seven days. The Mawi Heart Patch represents a significant advancement in cardiac monitoring technology, with the potential to enhance patient outcomes and contribute to saving lives.

In June 2024, Stryker, a US-based manufacturer of medical equipment, acquired Artelon for an undisclosed sum. This acquisition is intended to expand its product portfolio in joint preservation and soft tissue reconstruction. Artelon focuses on developing innovative biomaterials for soft tissue reinforcement and repair, especially in the areas of sports medicine and extremities procedures. Artelon is based in Georgia and specializes in medical equipment manufacturing.

Major companies operating in the cardiovascular and soft tissue repair patches market include B Braun, Baxter International Inc., CorMatrix Cardiovascular Inc., Cryolife Inc., Edwards Lifesciences Corporation, LeMaitre Vascular Inc., Anteris Technologies Limited, Abbott Laboratories, Terumo Medical Corporation, Integra LifeSciences Corporation, W. L. Gore & Associates Inc., Arthrex Inc., Johnson & Johnson, Stryker Corporation, LifeCell Corporation, Medtronic Inc., ACell Inc., Tissue Regenix Group Plc, Aroa Biosurgery Ltd., Zimmer Biomet, LifeNet Health Inc., Becton Dickinson and Company, Boston Scientific Corporation, Cook Medical, Endologix Inc., Getinge AB, Vascular Solutions Inc., AngioDynamics Inc., Merit Medical Systems Inc., Penumbra Inc., Glycar SA Pty Ltd., Biointegral Surgical Inc., Admedus Ltd., LabCor Corp., Smith & Nephew plc, Organogenesis Inc.

Cardiovascular and soft tissue repair patches are artificial tissues created in the laboratory, composed of tissues grown in vitro and polymers. These patches serve the purpose of restoring damaged body tissues, providing mechanical regeneration support for injured myocardium layers, and reinstating the functional characteristics of damaged tissues for the treatment of cardiovascular diseases.

The primary raw materials used in the production of cardiovascular and soft tissue repair patches include ePTFE (expanded Polytetrafluoroethylene), biomaterial and tissue-engineered material, and other relevant raw materials. ePTFE, a material commonly used in medical devices like catheters and cardiac sutures, is composed of tetrafluoroethylene polymer units and is known for its biocompatible properties. The resulting products include synthetic patches and biological patches, with applications ranging from cardiac repair to various heart-related conditions such as atrial septal defect, ventricular septal defect, and vascular repair. The end users of cardiovascular and soft tissue repair patches encompass hospitals, ambulatory surgical centers, and specialty clinics.

The cardiovascular and soft tissue repair patches market research report is one of a series of new reports that provides cardiovascular and soft tissue repair patches market statistics, including cardiovascular and soft tissue repair patches industry global market size, regional shares, competitors with a cardiovascular and soft tissue repair patches market share, detailed cardiovascular and soft tissue repair patches market segments, market trends and opportunities, and any further data you may need to thrive in the cardiovascular and soft tissue repair patches industry. This cardiovascular and soft tissue repair patches market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

North America was the largest region in the cardiovascular and soft tissue repair patches market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiovascular and soft tissue repair patches market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the cardiovascular and soft tissue repair patches market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.

The cardiovascular and soft tissue repair patches market consists of sales of xenogeneic patch and allogeneic patch. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.